The U.S. Food and Drug Administration approved Icotyde (icotrokinra), an oral IL‑23 receptor antagonist from Johnson & Johnson and Protagonist Therapeutics, for moderate-to-severe plaque psoriasis. The clearance follows the Iconic phase III program that enrolled roughly 2,500 patients and met multiple primary endpoints across adult and adolescent cohorts. Regulators cited robust efficacy and a favorable safety profile across four pivotal trials, including head-to-head data versus an active comparator. The approval positions Icotyde as the first oral peptide IL‑23 blocker available to patients and a direct challenger to injectable IL‑23 biologics. J&J projects multi‑billion-dollar peak sales, and Protagonist shareholders responded in after‑hours trading. Clinicians and payers will watch how an oral IL‑23 agent reshapes prescribing patterns previously dominated by injectables and infusions.